20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19+0.00 (+1.30%)
Close on Nov 17, 2026Market cap $2.39MP/E –Yield –
20/20 Biolabs operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was -$1.92M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.92M | – |
| FY2024 | Dec 31, 2024 | -$2.60M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$605.46K | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$534.11K | – |
| Q1 FY2025 | Mar 31, 2025 | -$488.29K | – |
See a number that looks wrong?